Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include MicroRNA in disease regulation, Cancer-related molecular mechanisms research, Circular RNAs in diseases, and Cancer Immunotherapy and Biomarkers.
Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC.
MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review
Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer
Impact of the gut microbiome on response and toxicity to chemotherapy in advanced esophageal cancer
The pathogenesis of common Gjb2 mutations associated with human hereditary deafness in mice
Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients.
Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma.
Efficacy and safety of gemcitabine plus S-1 <i>vs.</i> gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma.
Genomic landscape and efficacy of HER2-targeted therapy in patients with <i>HER2</i>-mutant non-small cell lung cancer.
Necroptosis-related signatures identify two distinct hepatocellular carcinoma subtypes: Implications for predicting drug sensitivity and prognosis
Immune checkpoint inhibitor-related molecular markers predict prognosis in extrahepatic cholangiocarcinoma.
Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel SLC34A2-ALK (exon 1: exon 15) fusion
LLPS of FXR1 drives spermiogenesis by activating translation of stored mRNAs
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma.
Extracellular Matrix-Based Gene Expression Signature Defines Two Prognostic Subtypes of Hepatocellular Carcinoma With Different Immune Microenvironment Characteristics.
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies.
Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data.
Correction: Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer
In situ Detecting Lipids as Potential Biomarkers for the Diagnosis and Prognosis of Intrahepatic Cholangiocarcinoma.
Characteristics and Prognostic Nomogram for Primary Lung Lepidic Adenocarcinoma.
ZNF280A promotes lung adenocarcinoma development by regulating the expression of EIF3C.
Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression.
[Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report].
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer
TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT
Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression.